Ani Pharmaceuticals Inc (NASDAQ:ANIP)
| Market Cap | $1.56B-15.3% |
| Revenue (ttm) | $1.04B+25.9% |
| Net Income | $116.84M+206.8% |
| EPS | $5.01+207.4% |
| Shares Out | 22.73M |
| PE Ratio | 13.23 |
| Forward PE | 6.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 227,256 |
| Open | $69.70 |
| Previous Close | $69.13 |
| Day's Range | $68.49 - $70.22 |
| 52-Week Range | $67.14 - $87.76 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | $99.50(+45.15%) |
| Earnings Date | Feb 26, 2027 |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating ANIP in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 26, 2027Earnings report
$ANIP stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ANIP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ANIP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ANIP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ANIP Revenue by Segment or Geography
| Cortrophin Gel | $138.66M | 47.68% |
| Generic pharmaceutical products | $104.45M | 35.92% |
| ILUVIEN and YUTIQ | $22.25M | 7.65% |
| Brand royalties and other revenues | $11.46M | 3.94% |
| Brands | $9.98M | 3.43% |
| Other generic revenues | $3.98M | 1.37% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ANIP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ANIP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ANIP
| IJRiShares Core S&P Small-Cap ETF | $83.86M |
| AVUVAvantis U.S. Small Cap Value ETF | $59.54M |
| VTIVanguard Morningstar Total Stock Market ETF | $38.07M |
| IWMiShares Russell 2000 ETF | $37.27M |
| AFTYPacer CSOP FTSE China A50 ETF | $33.42M |
| PJPInvesco Pharmaceuticals ETF | $16.88M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ANIP’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings beat with strong revenue growth, strategic $560M rare disease acquisition, and positive analyst sentiment offset by Cortrophin supply constraints and narrowing guidance.
Recent Insider Activity
Insider Score Trend Over Time
-46.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| PJP | Invesco Pharmaceuticals ETF | 2.83% |
| SCAP | Infrastructure Capital Small Cap Income ETF | 2.32% |
| AFSC | abrdn Focused U.S. Small Cap Active ETF | 2.28% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 2.00% |
| RNIN | EA Series Trust - Bushido Capital US SMID Cap Equity ETF | 1.08% |
| RZG | Invesco S&P SmallCap 600 Revenue ETF | 1.01% |
| NTRL | First Trust Merger Arbitrage ETF | 0.90% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 0.75% |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | 0.56% |
| CAFG | Pacer US Small Cap Cash Cows Growth Leaders ETF | 0.55% |
| JSMD | Janus Henderson Small/Mid Cap Growth Alpha ETF | 0.50% |
| AIMS | Acuitas Small Cap Active ETF | 0.42% |
Weight is the stock’s share of each fund’s holdings.
